Showing 81 - 100 results of 605 for search '(( significant clinical increase ) OR ( significant advancements decrease ))', query time: 0.19s Refine Results
  1. 81
  2. 82
  3. 83

    Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation by Graeme Ewan Glass (17733711)

    Published 2023
    “…There are no relevant clinical trial data linking PBM with any significant adverse events, including the finding of a new or recurrent malignancy.…”
  4. 84

    Beware of covert enemies: Candida orthopsilosis malignant otitis externa with base of the skull osteomyelitis, a case report and review of literature by Junais Koleri (17280586)

    Published 2021
    “…The patient was treated presumptively with a prolonged course of antibiotics without clinical improvement, coupled with progression of radiological findings and significant disease extension. …”
  5. 85

    Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials by Mohamed Mahmoud Marey (18560902)

    Published 2024
    “…Aldafermin showed a dose-dependent improvement in the ≥30 % reduction in the liver fat content (RR: 2.16, 95 % CI [1.41 to 3.32]) and (RR: 5.00, 95 % CI [1.34 to 18.64]), alanine aminotransferase levels (MD: −19.79, 95 % CI [−30.28 to −9.3]) and (MD: −21.91, 95 % CI [−29.62 to −14.21]), aspartate aminotransferase levels (MD: −11.79, 95 % CI [−18.06 to −5.51]) and (MD: −13.9, 95 % CI [−18.59 to −9.21]), and enhanced liver fibrosis score (ELF) (MD: −0.13, 95 % CI [−0.29 to 0.02]) and (MD: −0.33, 95 % CI [−0.50 to −0.17]), in the 1 mg and 3 mg subgroups respectively. No significant differences were detected in the aldafermin group regarding histologic endpoints, lipid profile, metabolic parameters, and overall adverse effects, except for the increased occurrence of diarrhea in the aldafermin 3 mg subgroup.…”
  6. 86
  7. 87

    Obesity and menopause by Albert A. Opoku FRCOG (15955340)

    Published 2023
    “…Increasing life expectancy means women spend a significant part of their lives in the menopause. …”
  8. 88

    Risk factors for extubation-related complications in morbidly obese patients undergoing bariatric surgery: a retrospective cohort study by Ayten Saracoglu (8075222)

    Published 2025
    “…The most commonly associated comorbidities were hypertension and obstructive sleep apnea, with an odds ratio of 2.98 for hypertension and 2.15 for obstructive sleep apnea (95%CI 1.40–6.33, <i>p</i> = 0.005; and 95%CI 1.08–4.29, <i>p</i> = 0.03; respectively). Despite these clinically important results, after applying the Bonferroni correction, none of these associations remain statistically significant, as the corrected p-values are above the threshold of <i>p</i> = 0.0031.…”
  9. 89

    Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®) by Mohamed Abo Zeid (20020680)

    Published 2025
    “…Eligible studies were randomized clinical trials and observational studies assessing intracameral phenylephrine/ketorolac against control groups. …”
  10. 90
  11. 91
  12. 92
  13. 93

    The effect of sperm DNA fragmentation on intracytoplasmic sperm injection outcome by Kareim Khalafalla (14148807)

    Published 2021
    “…This cohort reported that the clinical reproductive outcomes of intracytoplasmic sperm injection showed no statistical significance with increase sperm DNA fragmentation levels. …”
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99

    Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer by Adviti Naik (673163)

    Published 2025
    “…<h3>Background</h3><p dir="ltr">Immunotherapy has significantly improved outcomes for cancer patients; however, its clinical benefits vary among patients and its efficacy across breast cancer subtypes remains unclear. …”
  20. 100